Chinese researchers have made a significant advancement in cancer immunotherapy by developing an efficient method to mass-produce powerful tumor-killing natural killer (NK) cells from stem cells. Led by Professor Jinyong Wang at the Institute of Zoology, Chinese Academy of Sciences, the team has created a scalable process that starts with CD34+ hematopoietic stem and progenitor cells (HSPCs) sourced from umbilical cord blood.
Traditionally, producing enough NK cells for therapy has been challenging due to limited expansion rates, high costs, and complex manufacturing. The new approach overcomes these barriers by engineering early-stage stem cells rather than modifying mature NK cells. This streamlined protocol allows one single CD34+ stem cell to generate up to 14 million induced NK (iNK) cells or approximately 7.6 million chimeric antigen receptor-engineered CAR-iNK cells.
The implications are substantial for clinical application. According to the researchers, just one-fifth of a typical cord blood unit could theoretically produce enough cells for thousands or even tens of thousands of treatment doses. This breakthrough paves the way for “off-the-shelf” allogeneic NK cell therapies that could be more readily available and affordable compared to current personalized approaches.
A key advantage of the technique lies in its efficiency during genetic modification. The method dramatically reduces the amount of viral vector material needed for inserting CAR constructs—by a factor of roughly 140,000 to 600,000 times less than traditional methods used on mature NK cells. Lower vector usage translates directly into reduced manufacturing costs and improved safety profiles, making large-scale production more feasible for widespread clinical use.
The study, published in Nature Biomedical Engineering, demonstrates that these stem cell-derived NK cells maintain high potency against tumors. CAR-iNK cells can be specifically designed to target particular cancer antigens, enhancing their precision in attacking leukemia and solid tumors while minimizing damage to healthy tissues. Early laboratory results show strong anti-tumor activity, positioning this technology as a promising complement or alternative to CAR-T cell therapies, which often come with higher risks of severe side effects.
This development arrives at a time when global interest in NK cell therapies is rapidly growing. Unlike CAR-T cells, NK cells generally present a lower risk of cytokine release syndrome and graft-versus-host disease, making them attractive for broader patient populations. The ability to generate massive quantities from readily available cord blood sources could help address supply shortages and enable faster treatment timelines.
Professor Wang’s team continues to refine the protocol, including exploration of pluripotent stem cell-derived approaches for even greater scalability. While the research is still in the preclinical stage, the dramatic expansion rates and cost efficiencies have generated excitement within the regenerative medicine and oncology communities.
Industry experts believe this Chinese breakthrough could accelerate the transition of NK cell therapies from experimental treatments to standard care options. As clinical trials advance, the technology holds potential to improve outcomes for patients with various blood cancers and solid tumors, particularly in cases where conventional therapies have limited success.
The innovation highlights China’s growing leadership in stem cell research and advanced immunotherapy. With further validation and regulatory progress, this mass-production method may soon contribute to more accessible, effective cancer treatments worldwide, bringing hope to millions of patients battling the disease.
